Size and productivity: a conditional approach for Italian pharmaceutical sector

2020 ◽  
Vol 54 (1) ◽  
pp. 1-12
Author(s):  
Pierluigi Toma
Author(s):  
G. N. Singh

India has emerged as a global player for pharmaceuticals. The pharmaceutical revolution of 1970-90 of Indian Pharma Industry had demonstrated that India could be self-sufficient in the manufacture of essential drugs at affordable prices. The turnover of Indian Pharmaceutical is over $30 billion in 2015 including $15 billion in exports.  It was a great honor to preside the 67th Indian pharmaceutical congress held in Mysore. The topic of Pharmacists for a Healthy India is close to my heart and being a regulator myself, I feel that the Pharmacy fraternity can play a much larger role in contributing to the healthcare system in India. Pharmacist as such are involved in a big way in the regulation of drugs, be it manufacture, be it sale or research and development. A contribution of the Pharmacists is there at every stage till the drug reaches the consumer safely. For this purpose, the society needs a pool of well qualified and experienced pharmacists, which requires regular updating of their knowledge to keep pace with the developments taking place in the pharmaceutical sector. The advancements in technology and the emerging challenges in the health sector require pharmacists to shoulder the responsibilities towards the utilization of scientific knowledge in the use of modern medicines and the protection of the public against dangers of wrong use of drugs. The Pharmacy Council of India on its part will have to ensure that the courses offered for creating a high technology based are calibrated in such a way that the education and skills developed suit to the requirements of the Pharmaceutical Industry as well as needs to the patients


2017 ◽  
Vol 6 (2) ◽  
pp. 1
Author(s):  
Albert Naiem Naguib ◽  
Eahab Elsaid ◽  
Abdel Moneim Elsaid

This study examines the relationship between dynamic capabilities (experience, routine, skills, firm characteristics, knowledge and technology) and competitive advantage sustainability in the Egyptian pharmaceutical sector. The data was collected using primary and secondary data sources. Primary data was collected from questionnaires distributed to 160 top managers in 20 pharmaceutical firms. The secondary data about pharmaceutical firms like rankings, revenues and market share was collected from external sources such as Intercontinental Marketing Service (IMS). The questionnaires examine six independent variables based on a five-scale Likert scale. The methodology used in the study is non-probability sampling (judgmental sampling), Cronbach’s alpha reliability coefficient and Chi-square tests. The results support the notion that there is a significant relationship between four of the six dynamic capabilities (experience, skills, firm characteristics and knowledge) and the competitive advantage sustainability for pharmaceutical firms in Egypt. Designing the questionnaire and formulating the questions to target the required field was challenging, given that the topic is dynamic and the business scene in Egypt has witnessed drastic political changes since January 2011. The study should assist pharmaceutical companies in Egypt in directing their investments properly and in determining the weaknesses in their dynamic capabilities that need to be addressed.


2021 ◽  
Vol 13 (12) ◽  
pp. 6525
Author(s):  
Diana Marieta Mihaiu ◽  
Radu-Alexandru Șerban ◽  
Alin Opreana ◽  
Mihai Țichindelean ◽  
Vasile Brătian ◽  
...  

The primary goal of this study was to determine the impact of mergers and acquisitions (M&A) and the environmental, social, and governance (ESG) sustainability scores of companies. In this regard, efforts to measure and analyze the evolution of a company’s performance, taking into account financial and non-financial measures using a score function, are adapted to the pharmaceutical sector. The sample consisted of 100 leading pharmaceutical companies, ranked by stock market capitalization, who registered 30% (n = 492) of the total M&A transactions over the study period (2010–2020). There was a direct and positive link between the M&A process and the evolution of company performance. The ESG score, as an indicator for measuring sustainability, has a positive and direct impact on company performance, indicating that a high ESG score determines an increase in company performance. A similar impact is identified for companies involved in M&A processes, meaning that companies in the pharmaceutical sector tend to register a performance improvement.


2004 ◽  
Vol 08 (06) ◽  
pp. 297-308

Ai Scientific Awarded R&D Start Grant. CSIRO Drug Effective against Bird Flu. AustCancer Commences Anti-cancer Vaccine Phase II Trial. New Approach against Cancer. Non-invasive Cancer Test. China’s Chemical Pharmaceutical Sector Q1 2003 Performance. International Generic Companies Target India’s Manufacture Infrastructure. Cardinal Health Sets up Regional Office in Singapore. BRV Enters Agreement with Genedata.


2021 ◽  
Vol 177 ◽  
pp. 59-68
Author(s):  
Ana Flávia Nogueira Pimentel ◽  
Monica Gomes Lima-Maximino ◽  
Marta Candeias Soares ◽  
Caio Maximino

2021 ◽  
Author(s):  
Obi Peter Adigwe

Abstract Background: Amongst other objectives, the National Drug Policy was designed to improve access to medicines, whilst also stimulating socioeconomic development. The policy was also intended to promote pharmaceutical research and development in Nigeria. Despite its criticality in the achievement of national Medicines’ Security, evidence suggests a policy failure with consequent implications on attendant national health indices. This study aimed at assessing the views of pharmaceutical sector practitioners and other stakeholders, on the status quo as well as on strategies that can improve access to health whilst developing the sector. Methods: Data were collected using questionnaires which were administered to stakeholders present during an event that focused on improving the Nigerian pharmaceutical sector. Questionnaires were completed and returned. Quantitative data were analyzed using Statistical Package for Social Sciences, whilst textual data were analysed using thematic analysis.Results: Majority (48%) of the study participants indicated that current policy ecosystem was hostile for pharmaceutical sector growth and development. Also, a considerable proportion (97.3%) of the study participants indicated that increased investment in health research could stimulate the development of the pharmaceutical sector. Majority of the study participants indicated the need for collaboration between pharmaceutical companies, research institutes and the petrochemical industry.Conclusions: This study consequently identified several critical factors that can stimulate development in the sector, including increased funding of research; stringent implementation of existing policies; and prioritization of pharmaceutical sector by government and other key stakeholders.


Sign in / Sign up

Export Citation Format

Share Document